Halneuron - (HALT-CINP / HAL-CINP-203)

July 20, 2026: Dogwood Therapeutics, Inc. (NASDAQ: DWTX) announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial (NCT06848348) of Halneuron in moderate-to-severe chemotherapy-induced neuropathic pain (CINP) following platinum and/or taxane therapy. The randomized, placebo-controlled study plans to enroll ~210–240 patients across ~25 U.S. sites; participants receive eight subcutaneous doses over 14 days and are followed for 28 days. The primary endpoint is change from baseline to week 4 in weekly average daily 24-hour recall pain intensity scores; secondary measures include sleep, fatigue, neuropathy symptoms, and overall health.

The company said HAL-CINP remains on track for a top-line readout from the four-week study in fall 2026. It also stated that in December an independent statistical review committee reviewed unblinded data and concluded Halneuron-treated patients showed separation vs placebo for pain improvement over four weeks; reported dropout rate is 4.5%. Halneuron has FDA Fast Track designation for CINP.

Dogwood also noted SP16 IV (LRP1 agonist) with a forthcoming Phase 1b CIPN trial fully funded by the National Cancer Institute.